Blog
Hair exosomes: what we know — and what remains experimental
Exosomes are biologically interesting signalling vesicles, but hair-loss treatment claims have moved faster than the clinical evidence. Small studies are encouraging; superiority over established treatments has not been proven.
Hair loss is a diagnosis before it is a treatment. Androgenetic alopecia, telogen effluvium, alopecia areata, nutritional deficiency and scarring alopecia do not share the same biology or the same treatment pathway.
What exosomes actually are
Exosomes are small extracellular vesicles released by cells. They can carry proteins, lipids and nucleic acids involved in cell-to-cell signalling. Laboratory studies suggest they can influence pathways relevant to inflammation, dermal papilla cells and hair-follicle cycling.
Cell and animal studies help explain why exosomes are being researched, but they cannot establish how much benefit a patient will receive — or whether one product is equivalent to another.
The diagnosis changes everything, and it is often missed
Before any treatment is considered, the type of hair loss determines what will and will not work. This matters more than the choice between treatments, because several common causes are reversible and need no regenerative product at all.
| Pattern | Typical picture | What it needs |
|---|---|---|
| Androgenetic alopecia | Gradual thinning, temples and crown in men, widening part in women | Medical therapy, sometimes with adjuncts or surgery |
| Telogen effluvium | Diffuse shedding two to three months after illness, surgery, childbirth or major stress | Usually self-resolving; identify and remove the trigger |
| Iron or thyroid related | Diffuse thinning with fatigue or other symptoms | Blood tests and correction of the deficiency |
| Alopecia areata | Discrete round patches, sometimes rapid | Specific medical treatment; not a regenerative add-on |
| Scarring alopecia | Scalp redness, scale, pain, loss of follicle openings | Urgent assessment — follicle loss is permanent |
| Traction | Loss along the hairline from tight styling | Change the styling before anything else |
Where follicles are being destroyed by an inflammatory process, the damage is permanent and the priority is stopping the process. Scalp redness, scaling, tenderness or visibly smooth areas without follicle openings warrant prompt assessment rather than a course of any regenerative treatment.
Telogen effluvium deserves the opposite emphasis. It looks alarming — handfuls of hair — but typically follows a trigger by two to three months and resolves on its own. It is also the situation in which an expensive treatment started at the point of maximum shedding will appear to work brilliantly, because recovery was already coming.
Clinical evidence is still early
Published human studies include small prospective cohorts, pilot trials and heterogeneous products and delivery methods. Some report increases in hair density or thickness, but sample sizes are limited and follow-up is often short.
The evidence does not currently justify claims that exosomes reliably “activate dormant follicles,” produce a predictable 3–6 month regrowth timeline, or outperform platelet-rich plasma. Those statements were too strong in the previous version of this article.
Source cells, purification, concentration, storage, formulation and route of administration can vary substantially. Results from one product cannot automatically be transferred to another.
Why hair studies flatter treatments
Hair growth is cyclical, and shedding fluctuates seasonally and with health, stress and nutrition. Someone typically seeks treatment when shedding is at its worst — which is, statistically, the point from which things are most likely to improve regardless of intervention. Uncontrolled studies and before-and-after photographs cannot separate treatment effect from that natural regression, which is why controlled trials matter more here than in many other areas.
Photographic technique compounds it. Hair density appears dramatically different with lighting angle, whether hair is wet or dry, parting position, styling and camera distance. Standardised photography exists precisely because casual before-and-after images are so easily — and often unintentionally — misleading.
How exosomes compare with established hair-loss options
| Approach | Evidence / role | Important limitation |
|---|---|---|
| Minoxidil / medical therapy | Established role for selected forms of androgenetic hair loss | Requires ongoing use and medical suitability assessment. |
| Low-level laser/light therapy | Evidence of modest benefit in selected androgenetic alopecia | Response varies and maintenance is usually required. |
| PRP | Growing clinical evidence, though protocols vary | Not universally effective and still technique-dependent. |
| Exosome products | Emerging, preliminary human evidence | Product standardisation and long-term safety data remain limited. |
| Hair transplant | Redistributes permanent donor follicles in suitable candidates | Surgical and dependent on donor supply and future hair-loss planning. |
One practical point about transplantation that applies regardless of which adjunct is chosen: surgery redistributes existing donor hair rather than creating new follicles, and hair loss continues in untreated areas afterwards. Medical therapy to preserve remaining hair is therefore usually part of a transplant plan rather than an alternative to it.
For surgical options, see our FUE hair transplant information. For non-surgical support, see laser therapy for hair growth and scalp electroporation.
Topical application and injection are not interchangeable
Exosome-containing products may be marketed for topical use, post-procedure application, microneedling-assisted delivery or injection. These routes have different safety and regulatory implications. A topical cosmetic product should not be described as if it has evidence equivalent to an injectable biologic.
Any procedure that disrupts the skin barrier adds considerations such as sterility, infection risk and the quality of the product being applied. A product formulated and regulated as a cosmetic is not automatically appropriate to introduce beneath the skin barrier, and that distinction is worth asking about directly.
Regulatory status deserves explicit discussion
Regulation varies by country and by product. In the United States, the FDA states that there are currently no FDA-approved exosome products for treating disease or conditions and has warned about unapproved products associated with adverse events. That does not automatically determine Singapore regulation, but it illustrates why the exact product and intended use matter.
Related Aquila information
See our exosome-related treatment information for the specific formulation and route used by the clinic, rather than assuming all products are equivalent.
Questions worth asking before paying for exosome treatment
- What is my actual diagnosis? If this has not been established, that comes first.
- Which specific product, and what is its regulatory status here for this use?
- What is the source material and how is it processed?
- What published evidence exists for this product — not for exosomes as a concept?
- How does it compare with established options for my diagnosis?
- What would count as success, and when should it be judged?
- What is the total cost of a full course, including maintenance?
For androgenetic hair loss, established medical therapy has decades of outcome data. Adding an emerging treatment to that is a defensible choice made knowingly; replacing it with one is not.
Who should have a hair-loss diagnosis before considering add-on treatments
- Sudden diffuse shedding after illness, pregnancy or major stress
- Patchy hair loss
- Scalp redness, scale, pain or scarring
- Rapid progression
- Possible iron, thyroid or nutritional deficiency
- Hair loss associated with new medication or systemic symptoms
An add-on regenerative treatment should not delay investigation of a treatable cause. Iron studies and thyroid function are inexpensive, quick and occasionally explain the whole picture — which is a considerably better outcome than an expensive course of anything.
Questions patients ask
Do exosomes regrow hair?
Human evidence is early and preliminary. Small studies report changes in density, but superiority over established treatments has not been demonstrated.
Are exosome products all the same?
No. Source cells, purification, concentration, storage and route vary substantially, so results from one product cannot be transferred to another.
Why do hair treatment before-and-afters look so convincing?
Because people seek treatment when shedding peaks, which is when improvement is most likely anyway, and because lighting, wetness, parting and styling change apparent density dramatically.
My hair started falling out three months after being unwell — what is that?
That pattern suggests telogen effluvium, which typically follows a trigger by two to three months and usually resolves on its own once the trigger has passed.
Which type of hair loss is urgent?
Scarring alopecia. Scalp redness, scaling, tenderness or smooth areas without follicle openings mean follicles are being destroyed permanently and need prompt assessment.
Should I have blood tests first?
Often yes. Iron and thyroid abnormalities are inexpensive to check and occasionally explain the entire picture, which is a better outcome than any course of treatment.
Is exosome treatment better than PRP?
Not demonstrated. PRP has a larger, though still variable, evidence base, and no head-to-head evidence establishes exosome superiority.
Can a topical exosome product be injected?
Not interchangeably. A product formulated and regulated as a cosmetic is not automatically appropriate beneath the skin barrier, and that is worth asking directly.
Are exosome products approved?
Regulation varies by country and product. The US FDA states there are no approved exosome products for treating disease and has warned about unapproved products.
Will a hair transplant stop further loss?
No. It redistributes existing donor hair, and loss continues in untreated areas, which is why medical therapy is usually part of a transplant plan rather than an alternative.
Should exosomes replace my minoxidil?
No. Established therapy has decades of outcome data. Adding an emerging treatment knowingly is defensible; replacing proven therapy with one is not.
What should I ask before paying?
Your diagnosis, the specific product and its regulatory status, what evidence exists for that product rather than the concept, how it compares with established options, and the full course cost.
Sources & further reading
This article is general educational information. Exosome products are heterogeneous and evidence remains emerging. Product composition, route, regulation and safety should be assessed individually. Hair loss should be diagnosed before experimental or adjunctive therapy is considered. Content reviewed by the medical team at Aquila Medical Center, Singapore. Last reviewed: 27 August 2026.
Hair loss needs a diagnosis before a regenerative add-on
Assessment can determine whether the priority is medical treatment, light therapy, surgery, investigation — or whether an emerging adjunct is reasonable.